Comparative analysis of efficacy and safety between D-TACE + HAIC + lenvatinib and D-TACE + lenvatinib in the treatment of unresectable massive hepatocellular carcinoma
Abstract Objective The aim of this study was to investigate the efficacy and safety of the combined treatment regimen of D-TACE, HAIC, and Lenvatinib in patients with massive hepatocellular carcinoma, with the goal of providing a safer and more effective therapeutic strategy for individuals sufferin...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-024-13179-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850127982204551168 |
|---|---|
| author | Haohao Lu Bin Liang Chuansheng Zheng Xiangwen Xia |
| author_facet | Haohao Lu Bin Liang Chuansheng Zheng Xiangwen Xia |
| author_sort | Haohao Lu |
| collection | DOAJ |
| description | Abstract Objective The aim of this study was to investigate the efficacy and safety of the combined treatment regimen of D-TACE, HAIC, and Lenvatinib in patients with massive hepatocellular carcinoma, with the goal of providing a safer and more effective therapeutic strategy for individuals suffering from massive hepatocellular carcinoma. Materials and methods A retrospective analysis was conducted using clinical data from 118 patients with unresectable massive hepatocellular carcinoma who underwent treatment at the Interventional Department of Wuhan Union Hospital between June 2018 and December 2021. Based on the treatment approach, the patients were divided into two groups: the D-TACE + HAIC + Lenvatinib group (N = 54) and the D-TACE + Lenvatinib group (N = 64). The primary study endpoints included the objective response rate (ORR), disease control rate (DCR), overall survival (OS), and progression-free survival (PFS) of the two groups. Additionally, the occurrence of treatment-related adverse events in both groups was considered as a secondary study endpoint. Results Following the treatment, the D-TACE + HAIC + Lenvatinib group exhibited significantly higher ORR and DCR compared to the D-TACE + Lenvatinib group (68.5% vs. 43.8%, 90.7% vs. 73.4%, P < 0.05). Moreover, the D-TACE + HAIC + Lenvatinib group demonstrated longer mPFS and mOS in comparison to the D-TACE + Lenvatinib group (8.6 months vs. 6.6 months, P = 0.005; 19.5 months vs. 14.1 months, P < 0.001). There was no statistically significant difference in the occurrence rate of common treatment-related adverse events between the TACE + HAIC + Lenvatinib group and the D-TACE + Lenvatinib group (P > 0.05). Conclusion The combined treatment regimen of D-TACE, HAIC, and Lenvatinib demonstrated superior therapeutic efficacy and safety in managing unresectable massive hepatocellular carcinoma. This combination therapy may serve as a viable option for improving the prognosis of patients with unresectable massive hepatocellular carcinoma. |
| format | Article |
| id | doaj-art-69a5980219534c8ea41ebfa8ed891f8d |
| institution | OA Journals |
| issn | 1471-2407 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-69a5980219534c8ea41ebfa8ed891f8d2025-08-20T02:33:31ZengBMCBMC Cancer1471-24072024-11-0124111410.1186/s12885-024-13179-5Comparative analysis of efficacy and safety between D-TACE + HAIC + lenvatinib and D-TACE + lenvatinib in the treatment of unresectable massive hepatocellular carcinomaHaohao Lu0Bin Liang1Chuansheng Zheng2Xiangwen Xia3Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAbstract Objective The aim of this study was to investigate the efficacy and safety of the combined treatment regimen of D-TACE, HAIC, and Lenvatinib in patients with massive hepatocellular carcinoma, with the goal of providing a safer and more effective therapeutic strategy for individuals suffering from massive hepatocellular carcinoma. Materials and methods A retrospective analysis was conducted using clinical data from 118 patients with unresectable massive hepatocellular carcinoma who underwent treatment at the Interventional Department of Wuhan Union Hospital between June 2018 and December 2021. Based on the treatment approach, the patients were divided into two groups: the D-TACE + HAIC + Lenvatinib group (N = 54) and the D-TACE + Lenvatinib group (N = 64). The primary study endpoints included the objective response rate (ORR), disease control rate (DCR), overall survival (OS), and progression-free survival (PFS) of the two groups. Additionally, the occurrence of treatment-related adverse events in both groups was considered as a secondary study endpoint. Results Following the treatment, the D-TACE + HAIC + Lenvatinib group exhibited significantly higher ORR and DCR compared to the D-TACE + Lenvatinib group (68.5% vs. 43.8%, 90.7% vs. 73.4%, P < 0.05). Moreover, the D-TACE + HAIC + Lenvatinib group demonstrated longer mPFS and mOS in comparison to the D-TACE + Lenvatinib group (8.6 months vs. 6.6 months, P = 0.005; 19.5 months vs. 14.1 months, P < 0.001). There was no statistically significant difference in the occurrence rate of common treatment-related adverse events between the TACE + HAIC + Lenvatinib group and the D-TACE + Lenvatinib group (P > 0.05). Conclusion The combined treatment regimen of D-TACE, HAIC, and Lenvatinib demonstrated superior therapeutic efficacy and safety in managing unresectable massive hepatocellular carcinoma. This combination therapy may serve as a viable option for improving the prognosis of patients with unresectable massive hepatocellular carcinoma.https://doi.org/10.1186/s12885-024-13179-5Massive hepatocellular carcinomaDrug-eluting bead transarterial chemoembolizationHepatic arterial infusion chemotherapyTargeted therapyTyrosine kinase inhibitorLenvatinib |
| spellingShingle | Haohao Lu Bin Liang Chuansheng Zheng Xiangwen Xia Comparative analysis of efficacy and safety between D-TACE + HAIC + lenvatinib and D-TACE + lenvatinib in the treatment of unresectable massive hepatocellular carcinoma BMC Cancer Massive hepatocellular carcinoma Drug-eluting bead transarterial chemoembolization Hepatic arterial infusion chemotherapy Targeted therapy Tyrosine kinase inhibitor Lenvatinib |
| title | Comparative analysis of efficacy and safety between D-TACE + HAIC + lenvatinib and D-TACE + lenvatinib in the treatment of unresectable massive hepatocellular carcinoma |
| title_full | Comparative analysis of efficacy and safety between D-TACE + HAIC + lenvatinib and D-TACE + lenvatinib in the treatment of unresectable massive hepatocellular carcinoma |
| title_fullStr | Comparative analysis of efficacy and safety between D-TACE + HAIC + lenvatinib and D-TACE + lenvatinib in the treatment of unresectable massive hepatocellular carcinoma |
| title_full_unstemmed | Comparative analysis of efficacy and safety between D-TACE + HAIC + lenvatinib and D-TACE + lenvatinib in the treatment of unresectable massive hepatocellular carcinoma |
| title_short | Comparative analysis of efficacy and safety between D-TACE + HAIC + lenvatinib and D-TACE + lenvatinib in the treatment of unresectable massive hepatocellular carcinoma |
| title_sort | comparative analysis of efficacy and safety between d tace haic lenvatinib and d tace lenvatinib in the treatment of unresectable massive hepatocellular carcinoma |
| topic | Massive hepatocellular carcinoma Drug-eluting bead transarterial chemoembolization Hepatic arterial infusion chemotherapy Targeted therapy Tyrosine kinase inhibitor Lenvatinib |
| url | https://doi.org/10.1186/s12885-024-13179-5 |
| work_keys_str_mv | AT haohaolu comparativeanalysisofefficacyandsafetybetweendtacehaiclenvatinibanddtacelenvatinibinthetreatmentofunresectablemassivehepatocellularcarcinoma AT binliang comparativeanalysisofefficacyandsafetybetweendtacehaiclenvatinibanddtacelenvatinibinthetreatmentofunresectablemassivehepatocellularcarcinoma AT chuanshengzheng comparativeanalysisofefficacyandsafetybetweendtacehaiclenvatinibanddtacelenvatinibinthetreatmentofunresectablemassivehepatocellularcarcinoma AT xiangwenxia comparativeanalysisofefficacyandsafetybetweendtacehaiclenvatinibanddtacelenvatinibinthetreatmentofunresectablemassivehepatocellularcarcinoma |